LAGOG – Best of ASCO 2022 Annual Meeting

Página Inicial » Programação


Filtrar atividades
13:55 - 14:00 Abertura


14:00 - 14:45 Palestra

Módulo Câncer de Pele e Sarcomas

14:00 - 14:05
9501 - Survival data of PRADO - A phase 2 study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma

14:05 - 14:10
LBA2 - Phase III assessment of topotecan and cyclophosphamide and high-dose ifosfamide in rEECur: An international randomized controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma (RR-ES).
14:10 - 14:15
11508 - Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Results of the expanded cohort of myxoid liposarcoma of the randomized clinical trial from the Italian Sarcoma Group (ISG), the Spanish Sarcoma Group (GEIS), the French Sarcoma Group (FSG
and the Polish Sarcoma Group (PSG)
14:15 - 14:20
9507 - Nivolumab (NIVO) + tacrolimus (TACRO) + prednisone (PRED) +/- ipilimumab (IPI) for kidney transplant recipients (KTR) with advanced cutaneous cancers.
14:20 - 14:25
9515 - Atezolizumab (A), cobimetinib (C), and vemurafenib (V) in patients (pts) with BRAFV600 mutation–positive melanoma with central nervous system (CNS) metastases (mets): Primary results from phase 2 Tricotel study.
14:25 - 14:30
11505 - Long-term outcomes in patients with localized Ewing sarcoma treated with interval-compressed chemotherapy: A long-term follow-up report from Children’s Oncology Group study AEWS0031.
14:30 - 14:45
Painel de discussão
14:45 - 15:30 Palestra

Módulo cabeça e pescoço

14:45 - 14:53
6000 - Radiotherapy alone versus concurrent chemoradiotherapy in intermediate risk nasopharyngeal carcinoma: A multicentre, open-label, noninferiority, randomised phase III trial.
14:53 - 15:00
LBA6003 - Results of phase 3 randomized trial for use of docetaxel as a radiosensitizer in patients with head and neck cancer unsuitable for cisplatin-based chemoradiation.
15:00 - 15:08
6007 - A randomized phase II study evaluating concurrent or sequential fixed-dose immune therapy in combination with cisplatin and intensity-modulated radiotherapy in intermediate- or high-risk, previously untreated, locally advanced head and neck cancer
15:08 - 15:15
6008 - A phase II trial of pembrolizumab and cabozantinib in patients (pts) with recurrent metastatic head and neck squamous cell carcinoma (RMHNSCC).
15:15 - 15:30
Painel de discussão
15:30 - 16:00 Intervalo


16:00 - 17:30 Palestra

Módulo pulmão

16:00 - 16:06
8500 - Two cycles versus three cycles of neoadjuvant sintilimab plus platinum-doublet chemotherapy in patients with resectable non-small-cell lung cancer (neoSCORE): A randomized, single center, two-arm phase II trial.
16:06 - 16:12
8501 - Nivolumab + chemotherapy versus chemotherapy as neoadjuvant treatment for resectable stage IIIA NSCLC: Primary endpoint results of pathological complete response (pCR) from phase II NADIM II trial.
16:12 - 16:20
9000 - Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.
16:20 - 16:26
9004 - Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A.
16:26 - 16:32
9002 - KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
16:32 - 16:40
102 - Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non–small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.
16:40 - 16:46
Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC).
16:46 - 16:52
8504 - Comparison of quality of life in patients randomized to high-dose once daily (QD) thoracic radiotherapy (TRT) with standard twice daily (BID) TRT in limited stage small cell lung cancer (LS-SCLC) on CALGB 30610 (Alliance, Sub-study CALGB 70702).
16:52 - 17:00
8505 - Serplulimab, a novel anti-PD-1 antibody, plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small-cell lung cancer: An international randomized phase 3 study.
17:00 - 17:30
Painel de discussão
17:30 - 18:00 Palestra

Instituto Projeto Cura - Prêmio Renata Thormann Procianoy

18:00 - 18:05 Encerramento


08:25 - 08:30 Abertura


08:30 - 09:30 Palestra

Módulo ginecologia

08:30 - 08:38
LBA5500 - ATHENA–MONO (GOG-3020/ENGOT-ov45): A randomized, double-blind, phase 3 trial evaluating rucaparib monotherapy versus placebo as maintenance treatment following response to first-line platinum-based chemotherapy in ovarian cancer.
08:38 - 08:45
LBA5503 - Overall survival data from a 3-arm, randomized, open-label, phase 2 study of relacorilant, a selective glucocorticoid receptor modulator, combined with nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
08:45 - 08:53
LBA5504 - Randomized phase III trial on trabectedin (ET-743) single agent versus clinician’s choice chemotherapy in recurrent ovarian, primary peritoneal, or fallopian tube cancers of BRCA-mutated or BRCAness phenotype patients (MITO23).
08:53 - 09:00
5502 - Bevacizumab in first-line chemotherapy to improve the survival outcome for advanced ovarian clear cell carcinoma: A multicenter, retrospective analysis.
09:00 - 09:08
5506 - Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826.
09:08 - 09:15
5507 - Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205.
09:15 - 09:30
Painel de discussão
09:30 - 10:45 Palestra

Módulo mama

09:30 - 09:38
LBA501 - LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC).
09:38 - 09:45
503 - Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.
09:45 - 09:53
LBA3 - Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): results of DESTINY-Breast04, a randomized, phase 3 study
09:53 - 10:00
- LBA1001- Primary Results From TROPiCS-02: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients (Pts) With Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Advanced Breast Cancer.
10:00 - 10:08
LBA1003 - Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC):
Analyses from PALOMA-2
10:08 - 10:15
LBA1004 - A randomized phase II trial of fulvestrant or exemestane with or without Ribociclib after progression on Anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor
positive (HR+), HER2 negative metastatic breast cancer (MBC): MAINTAIN trial
10:15 - 10:45
Painel de discussão
10:45 - 11:00 Intervalo


11:15 - 11:45 Simpósio Satélite

Simpósio Satélite Daichii Sankyo/Astrazeneca - Câncer de mama com expressão aumentada de HER2, uma entidade única?

11:45 - 13:00 Palestra

Módulo gastrointestinal

11:45 - 11:53
LBA100 - Adjuvant chemotherapy guided by circulating tumor DNA analysis in stage II colon cancer: The randomized DYNAMIC Trial.
11:53 - 12:00
LBA5 - Single agent PD-1 blockade as curative-intent treatment in mismatch repair deficient locally advanced rectal cancer.
12:00 - 12:08
LBA1 - Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.
12:08 - 12:15
LBA3505 - Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer (mCRC): Results of the phase III randomized TRIPLETE study by GONO.
12:15 - 12:23
abstr 4003 - Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma
Interim results from DANTE, a randomized, multicenter, phase IIb trial of the FLOT-AIO German Gastric Cancer Group and Swiss SAKK.
12:23 - 12:30
abstr 4008 - Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: First results of the CONKO-007 trial.
12:30 - 13:00
Painel de discussão
13:00 - 13:30 Intervalo


13:30 - 14:45 Palestra

Módulo genitourinário

13:30 - 13:35
5000 - TheraP: 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel—Overall survival after median follow-up of 3 years (ANZUP 1603).
13:35 - 13:40
5002 - [68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy.
13:40 - 13:45
5009 - Cohort study of patients with oligorecurrent prostate cancer: Oncological outcomes of patients treated with salvage lymph node dissection via PSMA radioguided surgery.
13:45 - 13:50
4501 - Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER.
13:50 - 13:55
4508 - Final clinical results of pivotal trial of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive CIS and papillary nonmuscle-invasive bladder cancer (NMIBC).
13:55 - 14:00
5007 - Defining germline genetics of germ cell tumor: Implications for genetic testing and clinical management.
14:00 - 14:05
LBA5004 - Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC).
14:05 - 14:10
LBA4500 - EVEREST: Everolimus for renal cancer ensuing surgical therapy—A phase III study (SWOG S0931, NCT01120249).
14:10 - 14:15
5018 - BRCAAWAY: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects.
14:15 - 14:45
Painel de discussão
14:45 - 14:50 Encerramento